Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer

Climacteric

Volumn 18, Issue 2, 2015, Pages 252-259

  Buchholz, S ^a   Mogele M ^a   Lintermans, A ^b   Bellen, G ^c   Prasauskas, V ^d   Ortmann, O ^a   Grob, P ^d   Neven, P ^b   Donders, G ^c,e  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Femicare vzw   (Belgium)

^d Medinova Ltd   (Switzerland)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

aromatase inhibitors; Breast cancer; lactobacilli; quality of life; sexuality; vaginal atrophy; vaginal estriol

Indexed keywords

AGENTS USED INTRAVAGINALLY; AROMATASE INHIBITOR; ESTRIOL PLUS LACTOBACILLI; UNCLASSIFIED DRUG; ESTRIOL;

ADULT; ARTICLE; ATROPHIC VAGINITIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVOR; CLINICAL ARTICLE; CLINICAL STUDY; DYSPAREUNIA; EXPLORATORY RESEARCH; FEMALE; FEMALE SOMATIC SEXUAL EXPERIENCE INSTRUMENT QUESTIONNAIRE; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LOW DRUG DOSE; MEDICATION COMPLIANCE; OPEN STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SEXUALITY; TREATMENT DURATION; VAGINA ATROPHY; VAGINAL DRYNESS; ATROPHY; BREAST NEOPLASMS; CHEMICALLY INDUCED; INTRAVAGINAL DRUG ADMINISTRATION; LACTOBACILLUS; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VAGINAL DISEASES;

ADMINISTRATION, INTRAVAGINAL; AROMATASE INHIBITORS; ATROPHY; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTRIOL; FEMALE; HUMANS; LACTOBACILLUS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VAGINAL DISEASES;

EID: 84924655961     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.991301     Document Type: Article

References (30)

1. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519-30
2. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669-80
3. Pumo V, Milone G, Iacono M, et al. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res 2012;4:61-5
4. Yanez B, Thompson EH, Stanton AL. Quality of life among Latina breast cancer patients: a systematic review of the literature. J Cancer Surviv 2011;5:191-207
5. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14(Suppl 1):S20-40
6. Berman JR. Physiology of female sexual function and dysfunction. Int J Impot Res 2005;17(Suppl 1):S44-51
7. Basson R, Berman J, Burnett A, et al. Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. J Urol 2000;163:888-93
8. Basson R. The female sexual response: a different model. J Sex Marital Ther 2000;26:51-65
9. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94
10. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76
11. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584-7
12. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med 2000;9(Suppl 1):S25-32
13. Krause M, Wheeler TL, Snyder TE, Richter HE. Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg 2009;15:105-14
14. Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014;145:371-9
15. Donders GG, Van Bulck B, Van de Walle P, et al. Effect of Lyophilized lactobacilli and 0.03 mg estriol (Gynoflor®) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest 2010;70:264-72
16. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005;112:234-40
17. Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy: a double-blind randomized trial followed by open-label maintenance therapy. Climacteric 2013;16:347-55
18. Kanne B, Patz B, Wackerle L. [Local treatment of vaginal infections with Doederlein bacteria and estriol in climacterium and senium]. Frauenarzt 1986;3:35-40
19. Kanne B, Jenny J. [Local administration of low-dosed estriol and viable Lactobacillus acidophilus in the post-menopausal period]. Gynäkol Rundsch 1991;31:7-13
20. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753-60
21. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8: 549-59
22. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005;2(Suppl 3): 154-65
23. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-31
24. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl 1):S46-52
25. Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer survivors. Semin Oncol 2006;33:696-707
26. Wylie KR. Sexuality and the menopause. J Br Menopause Soc 2006;12:149-52
27. Gast MJ, Freedman MA, Vieweg AJ, De Melo NR, Girao MJ, Zinaman MJ. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009;16:247-56
28. Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008;5:132-8
29. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004;11: 120-30
30. Semmens JP, Tsai CC, Semmens EC, Loadholt CB. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol 1985;66:15-18